Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Mazdutide vs Orlistat: Orlistat has the stronger overall evidence (6 vs 5/10); they're alternatives for manage weight — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Orlistat wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Mazdutide and Orlistat have evidence — compare verdict strength side-by-side.
Investigational / China-only dosing: once-weekly subcutaneous injection, dose-escalated over several weeks. Trial maintenance doses studied were 4 mg, 6 mg, and 9 mg once weekly (lower doses used during titration to limit GI effects). There is no FDA-approved regimen.
Any time of day
Once-weekly subcutaneous injection (investigational; China-approved as Xinermei)
Prescription Xenical: 120 mg three times daily (360 mg/day), taken with or up to 1 hour after each main fat-containing meal. Over-the-counter Alli: 60 mg three times daily (180 mg/day). Skip the dose if a meal is missed or contains no fat. Used alongside a reduced-calorie diet in which fat supplies roughly 30% of energy — a higher-fat meal makes the gastrointestinal side effects markedly worse, not the weight loss better.
With meals
Xenical 120 mg capsule three times daily with meals (prescription)
and 2 more not shown
Months (dose-escalated)
Weeks to months
Weeks to months
Mostly during titration
4–12 weeks to onset; maximal by 6–12 months
Year 2 of continuous use
Years
3–12 months
Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.
JAMA (2026) · Rct · n=461
60-week phase-3 double-blind placebo-controlled RCT (GLORY-2) in 461 Chinese adults with obesity (BMI >=30), mazdutide 9 mg vs placebo
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.
N Engl J Med (2025) · Rct · n=610
48-week phase-3 double-blind placebo-controlled RCT (GLORY-1) in 610 Chinese adults with overweight/obesity, mazdutide 4 mg or 6 mg vs placebo
Mazdutide versus placebo in Chinese adults with type 2 diabetes.
Nature (2026) · Rct · n=320
Phase-3 RCT in 320 Chinese adults with type 2 diabetes inadequately controlled on diet/exercise, mazdutide 4/6 mg vs placebo for 24 weeks
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.
Diabetes Care (2004) · Rct · n=3305
4-year double-blind trial randomising 3,305 obese patients (BMI ≥30) to lifestyle changes plus orlistat 120 mg or placebo three times daily
Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.
Lancet (1998) · Rct · n=688
743 obese patients (BMI 28–47) entered a 4-week placebo lead-in at 15 European centres; 688 were randomised double-blind to orlistat 120 mg three times a day or placebo for 1 year on a 600 kcal/day-deficit diet, then reassigned for a second 52-week weight-maintenance period
Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.
JAMA (1999) · Rct · n=892
2-year randomised, double-blind, placebo-controlled trial at 18 US research centres; 1,187 obese adults (BMI 30–43) entered and 892 were randomised, with 223 placebo- and 657 orlistat-treated subjects in the intent-to-treat analysis
Orlistat has a higher evidence score (6/10 vs 5/10) and wins in 2 of 3 categories.
For manage weight, Orlistat has a higher relevance score (72 vs 66).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.